Postoperative subclinical AKI is common and associated with complications in non-critically ill patients undergoing cytoreductive and hyperthermic intraperitoneal chemotherapy surgery: The penkCHIP study

Postoperative subclinical AKI is common and associated with complications in non-critically ill patients undergoing cytoreductive and hyperthermic intraperitoneal chemotherapy surgery: The penkCHIP study

Saved in:

Bibliographic Details
Main Authors:	Louis Boutin, Taysir El Haj Hamed, Alexandre Mebazaa, François Dépret
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2025-06-01
Series:	Indian Journal of Anaesthesia
Online Access:	https://journals.lww.com/10.4103/ija.ija_206_25
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pregnancy after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei
by: Renato Gomes Campanati, et al.
Published: (2014-01-01)

Postoperative subclinical AKI is frequent and is linked to a poor long-term prognosis in critically ill patients
by: Louis Boutin, et al.
Published: (2025-07-01)

Cytoreductive interventions in combination with hyperthermic intraperitoneal chemoperfusion in pseudomyxoma
by: A. G. Abdullayev, et al.
Published: (2014-08-01)

Peritoneal Dissemination of Hepatoid Carcinoma of the Ovary Treated with Cytoreductive Surgery and Hyperthermic Intraoperative Intraperitoneal Chemotherapy
by: Pedro Antonio Cascales Campos, et al.
Published: (2013-01-01)

Analysis of Bacterial and Fungal Infections after Cytoreduction Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Observational Single-Centre Study
by: Talat A. M. Albukhari, et al.
Published: (2019-01-01)

Intraoperative photodynamic therapy and hyperthermic intraperitoneal chemotherapy in cytoreductive treatment of patients with disseminated mucinous carcinoma of appendix
by: D. V. Sidorov, et al.
Published: (2021-02-01)

EXPERIENCE IN APPLYING THE TECHNOLOGY OF CYTOREDUCTIVE SURGERY WITH HYPERTHERMIC INTRAOPERATIVE INTRAPERITONEAL CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH PERITONEAL CARCINOMATOSIS
by: A. V. Shelekhov, et al.
Published: (2018-07-01)

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy outcomes in peritoneal carcinomatosis: 11-year tertiary-center experience
by: Burak Dinçer, et al.
Published: (2025-03-01)

The impact of urological resection and reconstruction on patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
by: Grace Hwei Ching Tan, et al.
Published: (2018-07-01)

Retrospective evaluation of anesthesia management and clinical outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
by: Ahmet Kaya, et al.
Published: (2025-07-01)

Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy applications in upper and lower gastrointestinal cancer, a review
by: Denise Drittone, et al.
Published: (2024-11-01)

Advances in the Treatment of Colorectal Cancer with Peritoneal Metastases: A Focus on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
by: Youngbae Jeon, et al.
Published: (2023-12-01)

Association between time to adjuvant chemotherapy and survival in ovarian cancer patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
by: Sergei Iugai, et al.
Published: (2025-04-01)

Overall survival post secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent colorectal cancer with peritoneal metastases
by: Raymond Hayler, et al.
Published: (2025-07-01)

The Hemodynamic Management and Postoperative Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Prospective Observational Study
by: Sohan Lal Solanki, et al.
Published: (2024-01-01)

High intra-abdominal pressure during hyperthermic intraperitoneal chemotherapy (HIPEC) following cytoreductive surgery (CRS) for peritoneal surface malignancies
by: Louis Choon Kit Wong, et al.
Published: (2022-12-01)

Some Aspects of Postoperative Management of Patients with Ovarian Cancer after Cytoreductive Surgery Using Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
by: D. D. Morikov, et al.
Published: (2022-05-01)

Prognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
by: Zhang Xinjing, et al.
Published: (2025-02-01)

The Controversy of Intraperitoneal Hyperthermic Chemotherapy for Ovarian Cancer
by: Lucian ALECU, et al.
Published: (2020-12-01)

Short-Term Postoperative Cognitive Dysfunction and Inflammatory Response in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Pilot Study
by: Hui Yu, et al.
Published: (2017-01-01)

Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia
by: Ahmed Abu-Zaid, et al.
Published: (2016-01-01)

Hyperthermic intraperitoneal chemotherapy after upfront cytoreductive surgery for stage III epithelial ovarian cancer: Follow‐up of long‐term survival
by: Ziying Lei, et al.
Published: (2025-05-01)

Postoperative leukopenia after cytoreductive surgery and hypertherm intraperitoneal chemotherapy for colorectal carcinomatosis– causes and implication on outcomes in a population-based study
by: Mattias Lepsenyi, et al.
Published: (2025-04-01)

Intraoperative hyperthermia is associated with increased acute kidney injury following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a retrospective cohort study
by: Shun-Cai Gao, et al.
Published: (2024-12-01)

Efficacy and safety of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: a systematic review and updated meta-analysis
by: Ahmad Azhar Marzuqi, et al.
Published: (2025-04-01)

Implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy. A feasibility study
by: Anastasios Pandraklakis, et al.
Published: (2024-12-01)

Immediate postoperative effects of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy using carboplatin on peritoneal tissue inflammatory and ischemic responses: an explorative porcine study
by: Petersen Elisabeth Krogsgaard, et al.
Published: (2025-04-01)

Risk factors for postoperative acute kidney injury after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: a meta-analysis and systematic review
by: Dengzhuo Chen, et al.
Published: (2025-02-01)

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy and intraoperative radiation therapy in the management of gastric cancer: a 10-year single center experience
by: Marwan M. Alaswad, et al.
Published: (2025-02-01)

OUR EXPERIENCE OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY FOR PATIENTS WITH ADVANCED GASTRIC CANCER
by: A. D. Kaprin, et al.
Published: (2016-01-01)

Cytoreductive surgery and hyperthermal intraperitoneal chemoperfusion in colorectal cancer and cancer of ovaries: our experience and perspectives of a new method
by: A. V. Malynovskyi, et al.
Published: (2020-10-01)

Digital Health Intervention to Reduce Malnutrition Among Individuals With Gastrointestinal Cancer Receiving Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy: Feasibility, Acceptability, and Usability Trial
by: Yu Chen Lin, et al.
Published: (2025-04-01)

Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study
by: Hua-Hsi Wu, et al.
Published: (2025-08-01)

Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status
by: Jane Gibson, et al.
Published: (2024-10-01)

Role of hyperthermic intraperitoneal chemotherapy in combination with an intraperitoneal port system in the treatment of patients with advanced ovarian cancer
by: V. V. Saevets, et al.
Published: (2022-01-01)

Prognostic value of neutrophil-to-lymphocyte ratio and CA 19–9 in overall survival of patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
by: Yanli Nie, et al.
Published: (2025-06-01)

Comment on “Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study”
by: Fu Lou, et al.
Published: (2025-08-01)

Comment on “Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study”
by: Yan Wang, et al.
Published: (2025-08-01)

Impact of body mass index on surgical and oncological outcomes after Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
by: Anne-Cécile Ezanno, et al.
Published: (2025-01-01)

Hyperthermic intraperitoneal chemotherapy (HIPEC) increases risk of local anesthetic systemic toxicity (LAST)
by: Masahiko Tsuchiya, et al.
Published: (2025-01-01)